22 December 2022 - US FDA has confirmed that the goal date for an approval decision on Alvotech’s license application for ...
20 December 2022 - Pfizer oral treatment remains available to eligible US patients under emergency use authorisation as a critical ...
15 December 2022 - AstraZeneca and MSD today announced that the US FDA has informed AstraZeneca that it will extend ...
22 November 2022 - IntelGenx today announced that the US FDA has accepted for review its Class 2 response to the ...
21 November 2022 - Recent company submission in response to FDA request extends PDUFA date by three months. ...
18 November 2022 - BLA submission on-going with US FDA. ...
18 November 2022 - Apellis Pharmaceuticals today announced that the US FDA has accepted Apellis’ unsolicited major amendment to the new ...
7 November 2022 - FDA requests submission of upcoming 3 year data analysis from Phase 3 GENEr8-1 trial. ...
3 November 2022 - Submission will be a major amendment to the new drug application, extending the review period by ...
28 October 2022 - FDA issues deferred action letter on AT-GAA regulatory filing due to the inability to conduct required manufacturing ...
26 October 2022 - The US FDA has delayed a meeting of its advisory panel to discuss Perrigo's over the ...
25 October 2022 - IntelGenx today announced that its previously undisclosed development candidate, buprenorphine buccal film, for which an abbreviated ...
25 October 2022 - PDUFA goal date set for 6 April 2023. ...
17 October 2022 - The new Prescription Drug User Fee Act action date set by the FDA is 25 April ...
3 October 2022 - Under the Prescription Drug User Fee Act (PDUFA) VII Commitment Letter, the FDA is creating the Split ...